Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
Journal Article (Journal Article)
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor that has demonstrated increased overall survival when added to standard chemotherapy regimens for metastatic colorectal cancer. Herein we report the cases of 2 patients who demonstrated prolonged survival times of almost 5 and 6 years, respectively, on various chemotherapy regimens that also included bevacizumab. Throughout most of their disease course, these patients maintained a good quality of life, with some adjustments of chemotherapy doses because of side effects. Bevacizumab was generally well tolerated in long-term use.
- Hurwitz, HI; Honeycutt, W; Haley, S; Favaro, J
- May 2006
Volume / Issue
- 6 / 1
Start / End Page
- 66 - 69
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)
- United States